Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.
You may also be interested in...
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
Although the label’s PD-L1 expression requirement could limit the addressable market, there is also potential for future combination with Seagen’s recently approved Tivdak.